An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
BioNTech SE (Nasdaq: BNTX) will report its first-quarter 2024 financial results on May 6, 2024. The Company will host a conference call and webcast to discuss the results and provide a corporate update for investors, financial analysts, and the general public.
BioNTech SE (Nasdaq: BNTX) pubblicherà i risultati finanziari del primo trimestre del 2024 il 6 maggio 2024. L'azienda organizzerà una conferenza telefonica e un webcast per discutere i risultati e fornire un aggiornamento aziendale per investitori, analisti finanziari e il pubblico generale.
BioNTech SE (Nasdaq: BNTX) informará sobre los resultados financieros del primer trimestre de 2024 el 6 de mayo de 2024. La empresa realizará una llamada de conferencia y una transmisión web para discutir los resultados y proporcionar una actualización corporativa para inversores, analistas financieros y el público en general.
BioNTech SE (Nasdaq: BNTX)는 2024년 5월 6일에 2024년 제1분기 재무 결과를 보고할 예정입니다. 회사는 투자자, 재무 분석가 및 일반 대중을 위한 기업 업데이트를 제공하며 결과를 논의하기 위해 전화 회의 및 웹캐스트를 주최할 것입니다.
BioNTech SE (Nasdaq: BNTX) annoncera ses résultats financiers pour le premier trimestre de 2024 le 6 mai 2024. L'entreprise organisera une conférence téléphonique et une webdiffusion pour discuter des résultats et fournir une mise à jour de l'entreprise aux investisseurs, analystes financiers, et au grand public.
BioNTech SE (Nasdaq: BNTX) wird am 6. Mai 2024 die Finanzergebnisse für das erste Quartal 2024 vorlegen. Das Unternehmen wird eine Telefonkonferenz und ein Webcast veranstalten, um die Ergebnisse zu diskutieren und ein Unternehmensupdate für Investoren, Finanzanalysten und die Öffentlichkeit zu geben.
Positive
None.
Negative
None.
MAINZ, Germany, April 22, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2024 on Monday, May 6, 2024. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (2:00 p.m. CEST) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.
To access the live conference call via telephone, please register via this link. Once registered, dial-in numbers and a PIN will be provided. It is recommended to register at least one day in advance. The slide presentation and audio of the webcast will be available via this link.
Participants may also access the slides and the webcast of the conference call via the “Events & Presentations” page in the Investor Relations section of the Company’s website at https://biontech.com/. A replay of the webcast will be made available shortly after the call and archived on the Company’s website for 30 days following the call.
About BioNTech
Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor (CAR) T cells, several protein-based therapeutics, including bispecific immune checkpoint modulators, targeted cancer antibodies and antibody-drug conjugate (ADC) therapeutics, as well as small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Biotheus, DualityBio, Fosun Pharma, Genentech, a member of the Roche Group, Genevant, Genmab, OncoC4, Pfizer and Regeneron.
Media Relations Jasmina Alatovic +49 (0)6131 9084 1513 Media@biontech.de
FAQ
When will BioNTech report its first-quarter 2024 financial results?
BioNTech will report its first-quarter 2024 financial results on May 6, 2024.
What is the ticker symbol for BioNTech?
The ticker symbol for BioNTech is BNTX.
How can investors access the conference call and webcast for BioNTech's financial results?
Investors can access the live conference call via telephone by registering in advance and accessing the webcast through the Company's website.
Where can participants find the slide presentation and audio of the webcast?
The slide presentation and audio of the webcast will be available on the 'Events & Presentations' page in the Investor Relations section of BioNTech's website.
Will there be a replay of the webcast available?
Yes, a replay of the webcast will be available shortly after the call and archived on BioNTech's website for 30 days following the call.
everyone achieves greatness at biontech! as one of the most rapidly growing biotechnology companies in europe, we’re working on revolutionary approaches in the fight against cancer and other diseases. over 400 dedicated, passionate pioneers achieve sensational success and promising breakthroughs time and again by forging new paths – and ensure people all around the world have hope for the future. you too can become a pioneer! http://biontech.de/ http://biontech.de/imprint/
